UCLA Researchers Develop Nanoparticle-Based Gene Editing Platform for Cystic Fibrosis Treatment

UCLA查看公司主页 researchers have achieved a significant breakthrough in gene therapy by developing a lipid nanoparticle-based system capable of delivering complete gene-editing components to treat cystic fibrosis. The study, published in Advanced Functional Materials, demonstrates successful insertion of a full-length healthy gene into human airway cells, potentially opening new treatment avenues for patients with severe mutations who don't respond to current therapies.

Revolutionary Non-Viral Gene Delivery System

The UCLA查看公司主页 team engineered lipid nanoparticles—the same technology used in mRNA vaccines—to simultaneously transport three critical gene-editing components: CRISPR (搜索)搜索该药品 machinery for precise DNA cutting, guide molecules for genomic targeting, and a complete DNA template encoding a functional CFTR (搜索)搜索该靶点 gene. This represents the first demonstration of packaging such complex molecular cargo, particularly a gene as large as CFTR, into a single non-viral delivery system.

"This work shows that we can package everything needed for precise gene insertion into a single, non-viral delivery system," said Dr. Steven Jonas, senior author and member of the UCLA查看公司主页 Broad Stem Cell Research Center. "That's a critical step toward developing gene therapies that can work across many different disease-causing mutations."

Addressing Treatment-Resistant Mutations

Cystic fibrosis results from mutations in the CFTR (搜索)搜索该靶点 gene, which encodes a channel responsible for moving chloride and water across airway cell surfaces. When this channel malfunctions, lung mucus becomes thick and sticky, trapping bacteria and causing chronic infections and progressive lung damage. While CFTR modulator drugs have transformed care for many patients, approximately 10% produce little or no CFTR protein, leaving these medications ineffective.

"For those patients, gene therapy isn't just an improvement—it's really the only option," explained Dr. Brigitte Gomperts, co-author and associate director of translational research at the stem cell center. "You have to give the cell the ability to make the protein in the first place."

Remarkable Functional Recovery

Testing in laboratory-grown human airway cells carrying severe cystic fibrosis mutations revealed promising results. The nanoparticles successfully delivered the healthy CFTR (搜索)搜索该靶点 gene to 3-4% of cells, yet this modest correction rate achieved 88-100% restoration of normal CFTR channel function across the entire cell population.

This outsized therapeutic effect stems from strategic codon optimization of the replacement gene, developed by collaborators in Dr. Donald Kohn's UCLA laboratory. The optimized gene design maximizes protein production without altering the protein itself, enabling even a small number of corrected cells to have significant impact.

"Getting all of that into a single particle—especially a gene as large as CFTR (搜索)搜索该靶点—is something that hadn't been shown before," said Ruth Foley, the study's first author and recent Ph.D. graduate from the Jonas lab. "If you can solve the 'big gene' problem, it opens the door for a lot of other diseases as well."

Advantages Over Traditional Approaches

Unlike viral vectors, which face manufacturing challenges, cargo size limitations, and immune recognition issues, the lipid nanoparticle platform offers several advantages. The system is modular, potentially more scalable, and could be more affordable than traditional gene therapies. Additionally, by inserting the corrected gene directly into the genome rather than delivering temporary messenger RNA, the approach could provide durable, long-lasting therapeutic effects.

"This kind of platform gives you room to iterate," Foley noted. "If you need to re-dose or adapt the cargo for a different disease, you're not starting from scratch."

Challenges and Future Directions

The primary challenge ahead involves reaching airway stem cells, which reside deep within the lung's protective lining and continuously regenerate airways throughout life. These cells represent the ideal target for lasting therapeutic benefit, but accessing them requires overcoming the lung's natural defense mechanisms and the thick mucus barrier characteristic of cystic fibrosis.

"These stem cells are long-lived and constantly regenerate the airway," said Gomperts, who is also a professor of pediatrics and pulmonary medicine at UCLA查看公司主页's David Geffen School of Medicine. "If you can correct them, you could, in theory, have a lasting source of healthy cells."

Broader Therapeutic Implications

The researchers envision applying this strategy to other genetic lung diseases and potentially conditions in other tissues caused by large genes with multiple possible mutations. With over 1,700 different CFTR (搜索)搜索该靶点 mutations capable of causing cystic fibrosis, the universal approach could address any of these errors in a single treatment rather than developing individual therapies for each mutation.

"This paper is a proof of concept," said Jonas, who is also an assistant professor of pediatrics and member of the California NanoSystems Institute. "It shows that we can package and deliver the right genetic cargo. The next challenge is getting it to the right cells in the body."

The research was supported by the National Institutes of Health, the Cystic Fibrosis Foundation, the California Institute for Regenerative Medicine, and the Cystic Fibrosis Research Institute. For patients currently lacking effective treatments, this work represents a promising path forward in the development of mutation-agnostic gene therapies.